Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins

a technology of ligand trap proteins and muscle wasting, which is applied in the direction of peptide/protein ingredients, immunological disorders, metabolism disorders, etc., can solve the problems of robbery of patient mobility and independence, bone diseases can be very painful, and bone diseases can be very serious, so as to prevent muscle wasting
US20190330307A1Inactive Publication Date: 2019-10-31ALIVEGEN INC
0 Cites 5 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
ALIVEGEN INC
Publication Date
2019-10-31
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin / activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a U.S. National Stage Application pursuant to 35 U.S.C. § 371 of PCT / US2017 / 057351, filed Oct. 19, 2017, which claims the benefit of U.S. Provisional Application No. 62 / 410,595, filed on Oct. 20, 2016, each of which is incorporated in its entirety by reference herein.BACKGROUND ART

[0002] Muscle wasting refers to the progressive loss of muscle mass and / or to the progressive weakening and degeneration of muscles, including skeletal or voluntary muscles, cardiac muscles controlling the heart (cardiomyopathies), and smooth muscles. Chronic muscle wasting is a condition (i.e., persisting over a long period of time) characterized by progressive loss of muscle mass, as well as muscle weakening and degeneration. The loss of muscle mass occurs when the rate of muscle protein degradation exceeds muscle protein synthesis.

[0003] Muscle wasting is a debilitating and life-threatening disease state, which has been associated with the d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More